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Abstract
The recently described transcriptomic switch to a mitosis program in castration-resistant prostate cancer (CRPC) suggests
that mitotic proteins may be rationally targeted at this lethal stage of the disease. In this study, we showed upregulation of
the mitosis-phase at the protein level in our cohort of 51 clinical CRPC cases and found centrosomal aberrations to also
occur preferentially in CRPC compared with untreated, high Gleason–grade hormone-sensitive prostate cancer (P,0.0001).
Expression profiling of chemotherapy-resistant CRPC samples (n=25) was performed, and the results were compared with
data from primary chemotherapy-naı ¨ve CRPC (n=10) and hormone-sensitive prostate cancer cases (n=108). Our results
showed enrichment of mitosis-phase genes and pathways, with progression to both castration-resistant and chemotherapy-
resistant disease. The mitotic centromere-associated kinesin (MCAK) was identified as a novel mitosis-phase target in
prostate cancer that was overexpressed in multiple CRPC gene-expression datasets. We found concordant gene expression
of MCAK between our parent and murine CRPC xenograft pairs and increased MCAK protein expression with clinical
progression of prostate cancer to a castration-resistant disease stage. Knockdown of MCAK arrested the growth of prostate
cancer cells suggesting its utility as a potential therapeutic target.
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Introduction
Prostate cancer is the second leading cause of cancer-specific
mortality in the United States [1], with most deaths occurring after
failure of androgen-deprivation therapy when the tumor grows as
castration-resistant prostate cancer (CRPC), killing the patient
within a median period of 18 months. Docetaxel-based chemo-
therapy has been established as the standard of care in CRPC,
with a small but definite survival benefit [2,3]. Identifying targets
for this terminal castration-resistant and chemotherapy-resistant
phase of disease thus represents an unmet need in prostate cancer
[4,5].
An important recent advance in this field was the demonstration
that the androgen receptor activates a distinct mitosis-phase
transcriptional program in CRPC but not in hormone-sensitive
prostate cancer (HSPC) [6], partially explaining the relative
success of docetaxel, an anti-mitotic chemotherapeutic agent used
to treat CRPC. Those results also suggest that other mitosis-phase
proteins may be potential targets for therapies treating this stage of
disease.
We sought to first validate the upregulation of the mitosis-phase
transcriptional program at the protein level in CRPC using clinical
CRPC and high-grade HSPC cases. We next compared the
transcriptomic profiles of localized CRPC samples that were
chemotherapy-resistant with CRPC chemotherapy-naı ¨ve tumors
and hormone-sensitive prostate cancers. Pathway analysis of data
from our in-house specimens and publicly available databases
identified enrichment of mitosis-related genes as the disease
progressed to both a castration-resistant and chemotherapy-
resistant stage. The mitotic centromere-associated kinesin
(MCAK), whose gene expression was upregulated in multiple
CRPC chemotherapy-resistant datasets, was selected for clinical
and functional validation. MCAK protein expression was
associated with clinical progression of prostate cancer, and its
knockdown arrested the growth of prostate cancer cells.
Results
CRPC tumors show augmented mitosis-phase protein
expression and centrosomal aberrations compared with
high-grade HSPC
To validate the putative transcriptomic switch to a mitosis-phase
program in CRPC at the protein level, we used nuclear
phosphohistone H3 immunostaining as a mitosis-phase marker,
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31259as histones are phosphorylated at the end of prophase and their
phosphorylation peaks at metaphase [7]. We quantitatively
examined tissue-microarray sections of HSPC and CRPC with
the Ariol image analysis system. Our tissue arrays included 557
cores and .250,000 nuclei from 75 clinical cases. Our results
showed significant upregulation of phosphohistone H3 in
castration-resistant prostatic carcinoma compared with HSPC
(Figures 1G–1I and Table S2). These results provide evidence that
Figure 1. Increased mitosis-phase and centrosomal protein expression in castration-resistant prostate cancer compared with high-
grade hormone-sensitive prostate cancer. Hematoxylin and eosin (H&E)-stained sections showing castration-resistant adenocarcinoma (A),
castration-resistant small cell carcinoma (B), and hormone-sensitive high-grade prostate carcinoma (C). Castration-resistant adenocarcinoma
immunostained with gamma tubulin (D) and p-histone H3 (G). Castration-resistant small cell carcinoma immunostained with gamma tubulin (E) and
p-histone H3 (H). Hormone-sensitive high-grade prostate carcinoma immunostained with gamma tubulin (F) and p-histone H3 (I). Asterisks indicate
significantly increased labeling for the mitosis-phase marker p-histone H3 (J) and centrosomal marker gamma-tubulin (K) in castration-resistant
prostate carcinoma compared to hormone-sensitive high-grade prostate carcinoma.
doi:10.1371/journal.pone.0031259.g001
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high-grade hormone-sensitive tumors with Gleason grades of 4/5
also showed significantly lower phosphohistone H3 expression
than castration-resistant tumors of the adenocarcinoma or small
cell carcinoma histologies (P,0.0001) (Figures 1G–1J and Table
S2). Given the vastly different transcriptional profiles and far more
aggressive clinical behavior of high Gleason–grade (Gleason
grades 4/5) prostate cancer compared with low Gleason–grade
(Gleason grade 3) prostate cancer, our data underscores the
distinctiveness of CRPC from all histological subtypes of HSPC.
In studying the mitosis phase, we also examined centrosome
abundance, since centrosomes are key players in cell division.
Gamma tubulin, a microtubule nucleator and marker of
centrosome amplification, showed significantly increased cytoplas-
mic labeling in castration-resistant disease when compared with
HSPC (P,0.0001) and high-grade HSPC (P=0.008) (Figures 1D–
1F and 1K and Table S3). This finding is in keeping with the
known role of centrosome amplification and genetic instability in
the progression of other cancers [8,9,10,11].
Upregulation of the mitotic apparatus in CRPC tumors
with progression to castration resistance and
chemotherapy resistance
We macrodissected tumor cells that were castration-resistant
and chemotherapy-resistant from localized non-metastatic frozen
surgical samples from 20 unique patients and five xenografts
derived thereof (Table S1). Transcriptomic profiling of total RNA
was performed on those tumor samples and five benign prostate
samples that were used to normalize our expression data. Our
array raw data is submitted to GEO (GSE 33277). As our data
were derived from both terminal castration-resistant and docetaxel
chemotherapy–resistant tumors, we compared the mRNA expres-
sion profile of these samples to that of samples from earlier stages
of prostate cancer progression. Specifically, we compared our data
to public gene-expression data derived from untreated HSPC
(GSE 21032, n=108) and chemotherapy-naı ¨ve CRPC (GSE
6811, n=10). Such meta-analyses are challenging given the
numerous variables that can affect the intensity of the hybridiza-
tion signal. For a more reliable comparison, we specifically chose
datasets of localized, non-metastatic HSPC and chemotherapy–
naı ¨ve CRPC samples that had been normalized to data from
pooled benign prostate samples or where gene-expression data
from benign prostate samples that permitted such normalization
was provided. As expected, we found overexpression of mitosis-
phase genes and pathways relative to untreated HSPC samples
from the Memorial Sloan Kettering Cancer Center dataset (GSE
21032). These results are in agreement with previous reports [6]
but use independent datasets and methodologies.
The University of Tokyo dataset (GSE 6811) is one of very few
that includes CRPC chemotherapy-naı ¨ve samples. Significance of
microarray (SAM) analysis comparing the CRPC chemotherapy-
naı ¨ve group with our CRPC chemotherapy-resistant group
identified two informative gene sets that consisted of 2,490
upregulated and 2,121 downregulated genes in the chemotherapy-
resistant group. Pathway analysis of these two gene sets performed
using Ingenuity Pathway Analysis demonstrated that several cell-
cycle regulation pathways were significantly enriched in the
upregulated gene set (Figure 2A). In particular, the chemotherapy-
resistant group exhibited significant overexpression of the mitosis-
involved pathway (Figure 2B), as compared with the chemother-
apy-naı ¨ve group (Figure S1). Furthermore, overlap analysis of
these two gene sets, as assessed by a hypergeometric distribution
model (Figure 2C) using mitosis-phase (M-phase) genes obtained
from the MSigDB database (http://www.broadinstitute.org/gsea/
msigdb/index.jsp), showed significant overlap with only those
genes that were upregulated in the chemotherapy-resistant group
(n=27; P=5.0610
27). The genes downregulated in the chemo-
therapy-resistant group did not significantly overlap with the M-
phase genes (n=9; P=0.416). This observation was supported by
gene set–enrichment analysis (GSEA; http://www.broadinstitute.
org/gsea/index.jsp, Version 3.7), which showed that the M-phase
gene set was significantly enriched in the chemotherapy-resistant
group at a false discovery rate (FDR) of ,10% (Figure 2D). These
analyses suggest that mitosis-associated genes and pathways may
be involved in mediating chemotherapy resistance.
Mitotic centromere-associated kinesin is associated with
progression to therapy resistance, while its silencing
inhibits prostate cancer cell growth
Examination of the specifically altered mitotic regulators in our
transcriptomic data led us to identify genes coding for the mitotic
kinesin family of motor proteins as being upregulated in CRPC
chemotherapy-resistant samples. These mitotic kinesins were also
upregulated in two other large CRPC chemotherapy-resistant
datasets from the University of Michigan (GDS 1439) and
Memorial Sloan Kettering Cancer Center (GSE 21032). We
selected the mitotic centromere-associated kinesin (MCAK) as a
target in prostate cancer because it was novel and there was
marked overexpression of the MCAK gene (P=1.55 610
215)i n
localized CRPC from the MD Anderson Cancer Center dataset
as compared to hormone sensitive prostate cancer cases (n=108)
from the Memorial Sloan Kettering Cancer Center dataset (GSE
21032). MCAK was also upregulated with progression to
metastatic CRPC within the Memorial Sloan-Kettering Cancer
Center cohort (P=3.73 610
210) (Figure S2). Moreover, we found
concordant expression of MCAK in both our human parent
CRPC tumors and murine xenografts derived from those tumors
(r=0.428) as shown in Figure S3. We subsequently measured
MCAK protein expression by immunohistochemical analysis of
tissue microarrays of independent hormone-sensitive (n=38) and
castration-resistant (n=51) cases. We found MCAK cytoplasmic
staining to be significantly associated with clinical progression to
castration-resistant disease (P,0.0001) (Figures 3A–D and Table
S4).
To determine the effects of knocking down MCAK in HSPC
and CRPC, we used two distinct sets of small interfering RNA
(siRNA) specific for MCAK to silence its expression in hormone-
sensitive LNCaP and castration-resistant chemotherapy-naı ¨ve C4-
2B prostate cancer cell lines. Both CRPC and HSPC cell lines
showed abundant intrinsic MCAK protein expression and both
showed growth inhibition after 3 days of MCAK knockdown with
the first siRNA(si-MCAK #1) as assessed by an MTT assay
(Figure 4A–D) (C4-2B: 3 d, P=5.45610
27; 4 d, P=4.85610
210;
5 d, P=3.78610
28; LNCaP: 3 d, P=1.43610
23;4 d ,
P=3.86610
25; 5 d, P=1.48610
25). Similar results from the
second set of siRNA (si-MCAK #2) are shown in Figure S4.
Discussion
In this study, we have extended the findings of Wang et al [6] by
validating, at the protein level, the transcriptomic switch to a
mitosis program in an independent set of CRPC clinical samples
and showing that differences between castration resistant and
untreated hormone sensitive prostate cancers are maintained even
when comparing high Gleason grade prostate cancers. This is an
important finding given the different transcriptomic programs seen
in prostate cancers with low and high Gleason grades [12] that
reflect their dramatically differing clinical behavior. We have also
MCAK Is a Target in Lethal Prostate Cancer
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in keeping with the abnormal cell division seen in other advanced
cancers. These results support the concept that CRPC is
biologically distinct and not merely an extension of high-grade
hormone sensitive prostate cancer, despite their histological
similarities and propensity for clinical aggressiveness.
By comparing transcriptomic profiles of CRPC surgical samples
that were chemotherapy-naı ¨ve with our CRPC chemotherapy-
resistant data, we found enrichment of mitotic-phase proteins and
pathways in the chemotherapy-resistant tumors. Among the
mitosis-related genes, we selected the mitotic kinesin family of
motor proteins for further study—in particular MCAK, which has
not been previously studied in prostate cancer. Mitotic kinesins are
known to play a crucial role in regulating the mitotic spindle
apparatus during cell division. They are involved in cellular
proliferation and are regulated by aurora-B kinase [13].
Progression of lung, brain, and colorectal cancer [14] [15] has
been associated with augmented kinesin expression, while its
inhibition has resulted in cell-cycle arrest in the mitosis phase
[16,17]. Mitotic centromere-associated kinesin is plentiful in
centrosomes, depolymerizes microtubules, and mediates the
transition from prometaphase to metaphase [18], among other
essential functions related to proper chromosome segregation [19]
during cell division. Overexpression of mitotic kinesins, which are
postulated to work by countering the microtubule-stabilizing effect
of taxane-based chemotherapy, has been linked to docetaxel
resistance in breast cancer [20], and MCAK overexpression has
been causally related to paclitaxel resistance [21].
Targeting mitotic kinesins is thus emerging as an attractive
treatment modality in cancers that are refractory to taxane-based
chemotherapies that act upon the mitotic spindle, since inhibition
of kinesin motor proteins does not directly target microtubules.
Moreover, mitotic kinesins are not expressed by neurons [22] and
are poor substrates for the P-glycoprotein efflux pump [23],
Figure 2. Enhancement of mitosis-phase genes and pathways with progression to chemotherapy-resistant disease. (A) Cell-cycle
regulation pathways are significantly upregulated in the CRPC chemotherapy-resistant (TX) group compared with the CRPC chemotherapy-naı ¨ve
group. (B) Ingenuity Pathway Analysis.(IPA) of the upregulated gene set demonstrates that the canonical pathway of mitotic roles of polo-like kinase
is significantly associated with the CRPC chemotherapy-resistant group (P=0.004). The P value is calculated by Fisher’s Exact Test. The genes that are
upregulated in the CRPC chemotherapy-resistant group and are involved in this pathway are color-coded in red. The other genes that are included in
this pathway but are not in the upregulated gene set are indicated in white. (see text for identification of upreguated gene set in details). (C)
Significant overlap of the upregulated gene set in CRPC chemotherapy-resistant tumors with M-phase (n=27, P=5.00E-7) compared with the
downregulated gene set (n=9, P=0.416). (D) GSEA indicated that M-Phase was significantly enriched in the CRPC chemotherapy-resistant group at
FDR,10%.
doi:10.1371/journal.pone.0031259.g002
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multidrug resistance. Hence, mitotic kinesin inhibition is
hypothesized to induce mitosis-specific cell-cycle arrest that may
complement current chemotherapeutic protocols with fewer side
effects [18].
Different mitotic kinesins serve specific functions, and the role of
theseproteinsinprostatecancerhasonlybeenexploredwithrespect
to the most well-established member of this family, kinesin spindle
protein (KIF11/Eg5), whose silencing has been shown to inhibit the
growth of LNCaP and PC3 cell lines in vitro and in vivo [24,25].
Early-phase clinical trials in CRPC patients using the first
generation Eg5 inhibitor, ispinesib, have met with limited success
[26] [27]. However, newer-generation Eg5 inhibitors have been
reported to exhibit greater efficacy in vitro [28], and a third clinical
trial is currently recruiting patients from a range of malignancies,
including castration resistant prostate cancer (#NCT01065025).
In summary, we have shown enrichment of mitosis-phase
pathways and proteins as prostate cancer progresses to both a
castration-resistant and chemotherapy-resistant state. We exam-
ined the role of MCAK for the first time in prostate cancer and
showed that MCAK expression correlates with clinical progression
of this disease. Moreover, we demonstrated growth inhibition in
MCAK-silenced castration-resistant prostate cell lines. Together,
our results suggest that MCAK is a functionally important protein
in terminal prostate cancer. Follow-up studies based on the present
report should include using synthetic inhibitors directed against
MCAK (e.g., patent #7294640, Merck) in preclinical models and
in future clinical trials of prostate cancer.
Materials and Methods
Ethics statement
Hormone-sensitive and castration-resistant prostate cancer
tissue samples were obtained with approval from the from the
institutional review boards of The University of Texas MD
Anderson Cancer Center (Houston, Texas) and McGill University
(Montreal, QC, Canada). The tissue specimens used to develop
MDA PCa 79, MDA PCa 117-9, MDA PCa 124, MDA PCa 130,
MDA PCa 149-1, and MDA PCa 180-30 xenografts were derived
from tumor samples of surgical specimens (cystoprostatectomy,
radical prostatectomy, or pelvic exenteration) of a progressive
primary castration-resistant prostate cancer. Written informed
consent had been obtained from patients before sample acquisi-
tion, and samples were processed according to a protocol
approved by MD Anderson institutional review board, including
approval from the animal care and use committee. The lab
protocol numbers that covered the use of these samples are
MDACC LAB 03-0336 and LAB 09-0213.
Patient tissue samples
Molecularly profiled tissues were derived from MD Anderson
frozen tumor samples from patients with castration-and chemo-
therapy-resistant prostate cancer (n=20) and from benign
prostatic tissue controls (n=5). The castration-resistant chemo-
therapy-resistant samples were taken from salvage cystoprostatec-
tomies or pelvic exenterations. Murine xenografts derived from
five of these 20 tumors showing adenocarcinoma histology were
Figure 3. Overexpression of MCAK with clinical progression of prostate cancer. MCAK-immunostained sections of castration-resistant
adenocarcinoma (A), castration-resistant small cell carcinoma (B), and hormone-sensitive prostate carcinoma (C). D) Significantly increased labeling
for the mitotic centromere-associated protein MCAK with progression to CRPC, indicated by asterisks.
doi:10.1371/journal.pone.0031259.g003
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included in Table S1. Four tissue microarrays were used to
validate genomic data and consisted of formalin-fixed paraffin-
embedded samples from 58 patients with HSPC and 51 patients
with CRPC.
Expression profiling and analysis
Tumor mRNA expression was assessed using a human whole-
genome oligonucleotide microarray kit from Agilent (prod
#G4112F) according to the manufacturer’s protocol and as
described previously [29]. Our CRPC data was normalized to the
mean gene-expression values from five benign prostate samples to
find upregulated or downregulated genes using a log ratio value
.0.3 as the cut-off for informative genes present in more than
two-thirds of cases. We compared our expression profiling data to
the University of Michigan (GDS 1439), University of Tokyo (GSE
6811), and Memorial Sloan Kettering Cancer Center (GSE 21032)
datasets. For these datasets, normalization was performed against
their internal controls (benign samples).
Immunohistochemical analysis
Standard 3,39-diaminobenzidine (DAB) immunohistochemical
analyses of tissue microarrays were performed with a Dako
AutoStainer Plus (Dako) using a mouse anti-human monoclonal
MCAK antibody (Abgent AT2621a) at 1:50 dilution, a phospho-
histoneH3 antibody (Santa Cruz SC-8656) at 1:100 dilution, and a
gamma-tubulin antibody (Abcam AB27074) at 1:400 dilution, as
described previously [30]. Staining for gamma-tubulin and
MCAK was evaluated manually by assigning a percent positive
value to each case based on the aggregate immunohistochemical
labeling of all tissue cores belonging to that case.
Automated image analysis
The phosphohistone H3–positive nuclei were quantitatively
assessed using automated image analysis with Ariol software from
Applied Imaging (Genetix Ltd.). A custom-made, automated
nuclear quantitation algorithm using the Ariol software was
prepared based on color variations of the brown stain in the DAB-
positive cells versus the negative nuclear hematoxylin background
to achieve a percent positive per pre-selected area of representa-
tion on each slide.
Cell culture
C4-2B cells deposited at MD Anderson were developed after
serial passage of LNCaP cells in castrated hosts when the cells were
no longer responsive to androgen manipulation in animals (PMID:
8168083). LNCaP cells were obtained from American Type
Culture Collection (Manassas, VA, USA). Both cell lines were
cultured in RPMI1640 medium supplemented with 10% fetal
bovine serum at 37uC with an atmosphere of 5% CO2.
Xenograft studies
The tissue specimens used to develop the MDA PCa 79, MDA
PCa 117-9, MDA PCa 124, MDA PCa 130, and MDA PCa 149-1
xenografts were residual tissues from surgical resection (cystopros-
tatectomy or pelvic exenteration) of progressive primary CRPC.
Small tumor pieces were implanted into subcutaneous pockets of
6- to 8-week-old male CB17 SCID mice (Charles River
Figure 4. Growth inhibition of LNCaP and C4-2B cells by si-MCAK. A) Western blot confirming knockdown of MCAK by si-MCAK#1. Whole-
cell lysates from LNCaP cells transfected with si-control (C) or si-MCAK #1 (M) were collected at different time points after transfection, as indicated.
Tubulin was used as the loading control. B) MTT cell growth assay. LNCaP cells were treated the same as in A), and after a 24-h transfection, 4,000 cells
were seeded into each well of a 96-well plate (n=10 for each group) and the MTT assay was performed in a 24 h interval. C) Western blot confirming
knockdown of MCAK with si-MCAK#1. Whole-cell lysates from C4-2B cells transfected with si-control (C) or si-MCAK #1 (M) were collected at
different time points after transfection, as indicated. Tubulin was used as the loading control. D) MTT cell growth assay. C4-2B cells were transfected
with si-control and si-MCAK #1, respectively. After a 24-h transfection, 4,000 cells were seeded into each well of a 96-well plate and incubated for
different time periods, as indicated, followed by the MTT assay (n=10 for each group).
doi:10.1371/journal.pone.0031259.g004
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maintained in the mice, as the cells could not be grown in vitro. The
passage and tumor processing methods used were the same as
those reported previously (PMID: 18618013).
SiRNA transfection
The LNCaP or C4-2B cells were seeded into a 6-well plate at a
density of 5610
4 cells/well and cultured in RPMI1640 medium
supplemented with 10% FBS under normal tissue culture
conditions. After 20–24 h incubation, siRNA transfection was
performed usingLipofectamineRNAiMaxReagent from Invitrogen
(Invitrogen, cat # 56532) by following the manufacturer’s protocol.
Two sets of si-MCAK siRNA were used for the experiments. si-
MCAK #1 was purchased from Ambion (Ambion, cat # 4390824)
and the si-MCAK #2 was purchased from Dharmacon (Chicago,
IL, USA, cat # L-004955-00). The Universal Negative control #1
siRNA from Sigma (cat # SIC-001) was used as a control. The final
concentration of the siRNA was 50 nM.
Western blot analysis
MCAK monoclonal antibody was obtained from Abgent (cat #
AT2621a) and both b-actin (cat # sc-1616) and b-tubulin (cat #
sc-9104) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Western blotting was performed as described
[31]. Briefly, cell extracts containing 30 mg of protein were
resolved by 10% SDS-PAGE electrophoresis, transferred to
Hybond ECL nitrocellulose membranes (Amersham Pharmacia
Biotech) or polyvinylidene fluoride membranes (Cat #
IPVH20200) from Millipore (Millipore Corporation, cat. #
IPVH20200), blocked in 5% nonfat milk in 16 Tris-buffered
saline plus 0.05% tween-20 (pH 8.0) and probed with primary
antibodies at concentrations of 1:1000 for MCAK and 1:2500 for
b-actin or b-tubulin. The secondary antibodies were used at
concentrations of 1:10,000. The proteins were visualized using the
SuperSignal West Pico Chemiluminescent Substrate (Prod #
34708) or SuperSignal West Femto Maximum Sensitivity
Substrate (Prod # 34096) from Pierce (Pierce Chemical, Rockford,
IL, USA).
Cell proliferation assays
Cell proliferation was determined by an MTT absorbance
assay. The cells transfected with either control siRNA (si-control)
or MCAK siRNA (si-MCAK) were trypsinized from the dishes at
24 h post transfection and 4,000 cells in 200 ml complete medium
were seeded into each well of a 96-well plate (n=10). The cells
were allowed to attach for 24 h in the complete medium, and the
MTT assay was performed at 24 h intervals subsequently. After a
2.5 h incubation with 50 uM MTT reagent in normal cell culture
conditions, the wells were emptied by vacuum aspiration, and
200 ml DMSO was added to each well. The absorbance was
measured at 590 nm with a microplate reader (MRX; Danatech
Laboratory).
Statistical analysis
Data are expressed as the mean +/2 s.d. Statistical analyses
were performed using Student’s t-test and the Wilcoxon rank-sum
test. Differences in means were evaluated using a two-tailed t-test,
assuming unequal variances. A P value#0.05 was considered
statistically significant.
Supporting Information
Figure S1 Mitosis pathways are not associated with the
downregulated gene set in CRPC chemotherapy-resis-
tant disease. Ingenuity Pathway Analysis (IPA) of the down-
regulated gene set shows that the canonical pathway of mitotic
roles of polo-like kinase is not significantly associated with the
CRPC chemotherapy-resistant group (P=0.16). The P value is
calculated by Fisher’s Exact Test. The genes that are downreg-
ulated in the CRPC chemotherapy-resistant group and are
involved in this pathway are color-coded in green. The other
genes that are included in this pathway but are not included in the
downregulated gene set are indicated in white.
(TIF)
Figure S2 Increased MCAK transcript levels with
progression to CRPC. (A) MCAK shows transcriptomic
upregulation in localized CRPC (P=1.55610
215) and (B)
metastatic CRPC (P=3.73610
210) compared to HSPC.
(TIF)
Figure S3 Concordance of MCAK gene expression
between CRPC mouse xenografts (MDA-79, MDA-117,
MDA-130, MDA-149) and their corresponding human
parent tumors (r=0.428).
(TIF)
Figure S4 Growth inhibition of LNCaP and C4-2B cells
by si-MCAK #2. A) Western blot confirming knockdown of
MCAK by si-MCAK #2. Whole-cell lysates from LNCAP cells
transfected with si-control (C) or si-MCAK #2 (M) were collected
at different time points after transfection, as indicated. Actin was
used as the loading control. B) MTT cell growth assays. LNCaP
cells were treated the same as in A), and after a 24 h transfection,
4,000 cells were seeded into each well of a 96-well plate (n=6 for
each group) and followed by MTT assay. C) Western blot
confirming knockdown of MCAK with si-MCAK #2. Whole-cell
lysates from C4-2B cells transfected with si-control (C) or si-
MCAK #2 (M) were collected at different time points after
transfection, as indicated. Actin was used as the loading control. *
indicates non-specific bands. D) MTT cell growth assays. C4-2B
cells were transfected with si-control and si-MCAK #2,
respectively. After a 24 h transfection, 4,000 cells were seeded
into each well of a 96-well plate and incubated for different time
periods, as indicated, followed by the MTT assay (n=5 for each
group).
(TIF)
Table S1 Abbreviations: CXPX – cystoprostatectomy;
PE – pelvic exenteration; TURP – transurethral resec-
tion; TAB – total androgen blockade (lupron + casodex);
LHRH – lupron; ORCH – bilateral orchiectomy; XRT –
radiation therapy. * Small cell carcinoma component was
profiled from a mixed histology small cell/adenocarcinoma tumor.
(DOC)
Table S2 Abbreviations: HSPC – hormone sensitive
prostate cancer; HSPC-HG – hormone sensitive prostate
cancer of high histologic grade (Gleason patterns 4/5);
CRPC-adeno – castration resistant prostate cancer with
adenocarcinoma histology; CRPC-SCC – castration
resistant prostate cancer with small cell carcinoma
histology.
(DOC)
Table S3 Abbreviations: HSPC – hormone sensitive
prostate cancer; HSPC-HG – hormone sensitive prostate
cancer of high histologic grade (Gleason patterns 4/5);
CRPC-adeno – castration resistant prostate cancer with
adenocarcinoma histology; CRPC-SCC – castration
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histology.
(DOC)
Table S4 Abbreviations: HSPC – hormone sensitive
prostate cancer; CRPC-adeno – castration resistant
prostate cancer with adenocarcinoma histology; CRPC-
SCC – castration resistant prostate cancer with small
cell carcinoma histology.
(DOC)
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